Real World Study Of The Clinical Profile And Treatment Outcomes Of Advanced Therapies For Ulcerative Colitis In Portugal

Back to Search
Print
Bookmark Trial

NCT04156672

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Ulcerative Colitis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Aged at least 18 years old

- Diagnosed with Ulcerative Colitis, confirmed by a gastroenterologist

- Treated with anti-TNF or anti-integrin or JAK inhibitors drugs for at least 16 weeks

- Followed at one of the participating centers when initiating and during the current treatment

- Signed informed consent

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Treated with anti-TNF or anti-integrin or JAK inhibitors drugs at induction phase


- Enrolled in randomized clinical trials or other experimental studies in the last 12
months prior to initiation of advanced therapy

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Ulcerative ColitisEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
NCT04624230
  1. Obu-shi, Aichi
  2. Maebashi, Gunma
  3. Sendai-shi, Miyagi
  4. Izumi, Osaka
  5. Saitama-shi, Saitama
  6. Osaka,
  7. San Francisco, California
  8. San Francisco, California
  9. San Francisco, California
  10. Miami, Florida
  11. Lake Success, New York
  12. New Hyde Park, New York
  13. New York, New York
  14. New York, New York
  15. New York, New York
  16. Kurume-shi, Fukuoka
  17. Takatsuki, Osaka
  18. Bunkyo-ku, Tokyo
ALL GENDERS
2 Years+
years
MULTIPLE SITES
Ulcerative ColitisTITRATE (inducTIon for acuTe ulceRATivE Colitis)
NCT03937609
  1. Amsterdam,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Ulcerative ColitisTofacitinib Response in Ulcerative Colitis - a Real World Prospective Multi-center Study
NCT03772145
  1. Chapel Hill, North Carolina
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Ulcerative ColitisXeljanz and Healthy Diet
NCT04505410
  1. Miami, Florida
  2. Miami, Florida
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Real World Study Of The Clinical Profile And Treatment Outcomes Of Advanced Therapies For Ulcerative Colitis In Portugal
Official Title REal-world Study of the Clinical Profile and Treatment Outcomes of Advanced Therapies for Ulcerative Colitis in Portugal-READ UC
Brief Summary This study aims to characterize the Portuguese population of patients with moderate-to-severe UC receiving advanced therapies, by describing clinical and sociodemographic characteristics, and remission outcomes . The clinical, biochemical, endoscopic, and histological outcomes will also be described, as well as frequency of selected EIM, comorbidities and the uptake of preventive care measures and hospitalizations .
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Other
Time Perspective: Cross-Sectional
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population Patients followed at Portuguese gastroenterology services, presenting moderate-to-severe Ulcerative Colitis and receiving advanced therapies (i.e., anti-TNF or anti-integrin or JAK inhibitors drugs) for at least 16 weeks.
Condition Ulcerative Colitis
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Withdrawn
Actual Enrollment
 (submitted: January 25, 2021)		0
Original Estimated Enrollment
 (submitted: November 6, 2019)		310
Estimated Study Completion Date April 30, 2021
Estimated Primary Completion Date April 30, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Aged at least 18 years old
  • Diagnosed with Ulcerative Colitis, confirmed by a gastroenterologist
  • Treated with anti-TNF or anti-integrin or JAK inhibitors drugs for at least 16 weeks
  • Followed at one of the participating centers when initiating and during the current treatment
  • Signed informed consent

Exclusion Criteria:

  • Treated with anti-TNF or anti-integrin or JAK inhibitors drugs at induction phase
  • Enrolled in randomized clinical trials or other experimental studies in the last 12 months prior to initiation of advanced therapy
Sex/Gender
Sexes Eligible for Study:All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT04156672
Other Study ID Numbers A3921353
READ UC ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement
Plan to Share IPD:No
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date January 2021